What is AbCellera Biologics Inc.'s 2029?

AbCellera Biologics Inc. (ABCL) reported 2029 of $3.73M in Q1 2026.

AbCellera Biologics Inc. ABCL 2029

2029 at other companies

BridgeBio PharmaBBIO

——

RevvityRVTY

——

AbbottABT

——

Other financials

Income statement

See full

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

See full

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.84B+59.2%

Enterprise value$1.88B+100.0%

P/S23.3×-26.8×

Profitability

See full

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s 2029?: AbCellera Biologics Inc. (ABCL) reported 2029 of $3.73M in Q1 2026.